Ceftolozane-tazobactam activity against phylogenetically diverse clostridium difficile strains

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 7084-7085

  Gonzalez, Mark D ^a   Wallace, Meghan A ^a   Hink, Tiffany ^a   Dubberke, Erik R ^a   Burnham, Carey Ann D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CEFTOLOZANE; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CLASSIFICATION; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLOSTRIDIUM DIFFICILE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PHYLOGENY;

EID: 84946234354     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01670-15     Document Type: Article

References (19)

1. Cho JC, Fiorenza MA, Estrada SJ 2015. Ceftolozane-tazobactam: a novel cephalosporin/β-lactamase inhibitor combination. Pharmacotherapy 35: 701-715. http://dx.doi.org/10.1002/phar.1609.
2. Snydman DR, McDermott LA, Jacobus NV 2014. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother 58:1218-1223. http://dx.doi.org/10.1128/AAC.02253-13.
3. Dubberke ER, Reske KA, Seiler S, Hink T., Kwon JH, Burnham CA. 2015. Risk factors for acquisition and loss of C. difficile colonization in hospitalized patients. Antimicrob Agents Chemother 59:4533-4543. http://dx.doi.org/10.1128/AAC.00642-15.
4. Dubberke ER, Reske KA, Yan Y, Olsen M.A., McDonald LC, Fraser VJ. 2007. Clostridium difficile-associated disease in a setting of endemicity: identification ofnovel risk factors. Clin Infect Dis 45:1543-1549. http://dx.doi.org/10.1086/523582.
5. Slimings C, Riley TV 2014. Antibiotics and hospital-acquired Clostridium difficileinfection: updateofsystematic review and meta-analysis. J Antimicrob Chemother 69:881-891. http://dx.doi.org/10.1093/jac/dkt477.
6. Dubberke ER, Olsen MA 2012. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 55(Suppl 2):S88-S92. http://dx.doi.org/10.1093/cid/cis335.
7. Hall AJ, Curns AT, McDonald L.C., Parashar UD, Lopman BA. 2012. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths inthe United States, 1999-2007. Clin Infect Dis 55:216-223. http://dx.doi.org/10.1093/cid/cis386.
8. Solomkin J, Hershberger E, Miller B., Popejoy M, Friedland I, Steenbergen J., Yoon M, Collins S, Yuan G., Barie PS, Eckmann C. 2015. Ceftolozane-tazobactam plus metronidazole for complicated intraabdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60:1462-1471. http://dx.doi.org/10.1093/cid/civ097.
9. Wagenlehner FM, Umeh O, Steenbergen J., Yuan G, Darouiche RO. 2015. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385: 1949-1956. http://dx.doi.org/10.1016/S0140-6736(14)62220-0.
10. Zhou Y, Burnham CA, Hink T, Chen L., Shaikh N, Wollam A, Sodergren E., Weinstock GM, Tarr PI, Dubberke ER. 2014. Phenotypic and genotypic analysis of Clostridium difficile isolates: a single-center study. J Clin Microbiol 52:4260-4266. http://dx.doi.org/10.1128/JCM.02115-14.
11. Tenover FC, Tickler IA, Persing DH 2012. Antimicrobial-resistant strains of Clostridium difficile from North America. Antimicrob Agents Chemother 56:2929-2932. http://dx.doi.org/10.1128/AAC.00220-12.
12. Spigaglia P, Barbanti F, Mastrantonio P., European Study Group of Clostridium difficile (ESGCD). 2011. Multidrug resistance in European Clostridium difficile clinical isolates. J Antimicrob Chemother 66:2227-2234. http://dx.doi.org/10.1093/jac/dkr292.
13. Alasmari F, Seiler SM, Hink T, Burnham C.A., Dubberke ER. 2014. Prevalence and risk factors for asymptomaticClostridium difficilecarriage. Clin Infect Dis 59:216-222. http://dx.doi.org/10.1093/cid/ciu258.
14. Dubberke ER, Han Z, Bobo L., Hink T, Lawrence B, Copper S., Hoppe-Bauer J, Burnham C-AD, Dunne WM, Jr. 2011. Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections. J Clin Microbiol 49:2887-2893. http://dx.doi.org/10.1128/JCM.00891-11.
15. Hink T, Burnham CA, Dubberke ER 2013. A systematic evaluation of methods to optimize culture-based recovery of Clostridium difficile from stool specimens. Anaerobe 19:39-43. http://dx.doi.org/10.1016/j.anaerobe.2012.12.001.
16. Westblade LF, Chamberland RR, MacCannell D, Collins R., Dubberke ER, Dunne WM, Jr, Burnham CA. 2013. Development and evaluation of a novel, semiautomated Clostridium difficile typing platform. J Clin Microbiol 51:621-624. http://dx.doi.org/10.1128/JCM.02627-12.
17. Garner O, Mochon A, Branda J., Burnham CA, Bythrow M, Ferraro M, Ginocchio C., Jennemann R, Manji R, Procop G.W., Richter S., Rychert J, Sercia L, Westblade L., Lewinski M. 2014. Multi-centre evaluation of mass spectrometric identification of anaerobic bacteria using the VITEK MS system. Clin Microbiol Infect 20:335-339. http://dx.doi.org/10.1111/1469-0691.12317.
18. Freeman J, Bauer MP, Baines S.D., Corver J., Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH 2010. The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23:529-549. http://dx.doi.org/10.1128/CMR.00082-09.
19. Kuijper EJ, Coignard B, Tüll P, ESCMID Study Group for Clostridium difficile, EU Member States, European Centre for Disease Prevention and Control. 2006. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12(Suppl 6):S2-S18.